Alnylam Pharmaceuticals (ALNY) Interest & Investment Income (2016 - 2025)
Historic Interest & Investment Income for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q4 2025 value amounting to $26.6 million.
- Alnylam Pharmaceuticals' Interest & Investment Income fell 1414.94% to $26.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $111.5 million, marking a year-over-year decrease of 862.52%. This contributed to the annual value of $111.5 million for FY2025, which is 862.52% down from last year.
- As of Q4 2025, Alnylam Pharmaceuticals' Interest & Investment Income stood at $26.6 million, which was down 1414.94% from $28.7 million recorded in Q3 2025.
- In the past 5 years, Alnylam Pharmaceuticals' Interest & Investment Income ranged from a high of $32.1 million in Q3 2024 and a low of $225000.0 during Q3 2021
- Its 5-year average for Interest & Investment Income is $17.8 million, with a median of $23.2 million in 2023.
- In the last 5 years, Alnylam Pharmaceuticals' Interest & Investment Income crashed by 9178.83% in 2021 and then skyrocketed by 337555.56% in 2022.
- Over the past 5 years, Alnylam Pharmaceuticals' Interest & Investment Income (Quarter) stood at $495000.0 in 2021, then skyrocketed by 2743.84% to $14.1 million in 2022, then skyrocketed by 116.0% to $30.4 million in 2023, then rose by 2.02% to $31.0 million in 2024, then decreased by 14.15% to $26.6 million in 2025.
- Its Interest & Investment Income stands at $26.6 million for Q4 2025, versus $28.7 million for Q3 2025 and $27.5 million for Q2 2025.